Hepatic steatosis in obese patients: Clinical aspects and prognostic significance

Obesity Reviews

Volumn 5, Issue 1, 2004, Pages 27-42

  Festi, D ^a,d   Colecchia, A ^a   Sacco, T ^a,b   Bondi, M ^a,c   Roda, E ^a   Marchesini, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin resistance; Metabolic syndrome; Non alcoholic steatohepatitis; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; CYTOKINE; INSULIN SENSITIZING AGENT; TRIACYLGLYCEROL;

CLINICAL FEATURE; CYTOKINE RELEASE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PROGNOSIS; REVIEW; RISK FACTOR; STELLATE CELL;

BIOPSY; FATTY LIVER; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIVER; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 0842269198     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2004.00126.x     Document Type: Review

References (155)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO: Geneva, 1997.
2. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
4. Ezzati M, Lopez AD, Rodgers A, Van der Hoorn S, Murray CJL and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
5. Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003; 17: 977-986.
6. Angulo P. Non alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
7. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
8. James O, Day C. Non-alcoholic steatohepatitis. another disease of affluence. Lancet 1999; 353: 1634-1636.
9. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Met 2002; 16: 703-716.
10. Sabir N, Sermez Y, Kazil S, Zencir M. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 2001; 14: 121-128.
11. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
12. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Dis 2002; 2: 11-19.
13. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic Proc 1980; 55: 434-438.
14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.
15. Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. Am J Roentgenol 1985; 145: 753-755.
16. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiological studies. Gastroenterology 2003; 124: 248-250.
17. Poonawala A, Nair S, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-692.
18. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, Rosen CB, Batts KB. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614.
19. Evans CD, Oien KA, MacSween RNM, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002; 55: 689-692.
20. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79.
21. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effects of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226.
22. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003; 18: 124-138.
23. Hasan I, Gani RA, Machmud R. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia. J Gastroenterol Hepatol 2002; 17: A30.
24. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY. Prevalence of nonalcoholic fatty liver among administrative officiers in Shangai: an epidemiological survey. World J Gastroenterol 2003; 9: 1106-1110.
25. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population in Okinawa, Japan. Jpn J Med 1988; 27: 142-149.
26. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-2009.
27. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti M, Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosing and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1438-1442.
28. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
29. Yang SO, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acd Sci USA 1997; 94: 2557-2562.
30. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364.
31. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
32. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
33. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
34. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
35. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
36. Fiellin DA, Reid MC, O'Connor PG. Screening for alcohol problems in primary care. A systematic review. Arch Intern Med 2000; 160: 1977-1989.
37. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
38. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullogh AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
39. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
40. Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, Superina R, Flamm SL, Blei AT. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplantation 1993; 42: 548-551.
41. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui J, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman MD, George J. NASH and insulin resistance: insulin secretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
42. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AF, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
43. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffmann ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
44. WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. World Health Organization: Geneva, 1999, pp. 31-33.
45. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486-2497.
46. Marchesini G, Bugianesi E, Forlani G, Cerelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
47. Day C, James O. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998; 114: 842-845.
48. Harrison SA, Diehl AM. Fat and the liver. A molecular overview. Sem Gastrointest Dis 2002; 13: 3-16.
49. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Rev 2002; 23: 201-229.
50. Thorens B. Glucose transporters in the regulation of intestinal, renal and liver glucose fluxes. Am J Physiol 1996; 270: G451-G453.
51. Bollen M, Keppens S, Stalmans W. Specific features of glycogen metabolism in the liver. Biochem J 1998; 336: 19-31.
52. Foufelle F, Ferrè P. New perspectives in the regulation of hepatic glicolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366: 377-391.
53. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto H, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
54. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749-758.
55. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; i: 785-789.
56. Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284: E863-E873.
57. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002; 51: 2951-2958.
58. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97: 2714-2724.
59. Bjorkegren J, Beigneux A, Bergo MO, Maher JJ, Young SG. Blocking the secretion of hepatic very low density lipoprotein renders the liver more susceptible to fixed drug injury. J Biol Chem 2002; 277: 5476-5483.
60. Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horm Metab Res 1996; 28: 619-632.
61. Uygun A, Kadayifei A, Yesiloua Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3588.
62. Barzilai N, Wang J, Massilon D, Vuguin P, Hawakins M, Rossetti L. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997; 100: 3105-3110.
63. Saxena NK, Ikeda K, Rockey DC, Friedman SI, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771.
64. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodelling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-1410.
65. Unger RH. Lipotoxic diseases. Ann Rev Med 2002; 53: 319-336.
66. Molley MJ, Kane JP, Bacon B. A genetic mutation in the proliferators activated receptor alpha (PPAR-A) gene in patients with non-alcoholic steatohepatitis. Hepatology 2001; 34: 441.
67. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075.
68. Chavin KD, Yang SQ, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of UCP-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
69. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagal R, Kodowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
70. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa RE, Pratley PA, Tataranni H. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyper-insulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
71. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-E533.
72. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Comm 2003; 301: 1045-1050.
73. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003; 112: 91-100.
74. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
75. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes amd mitochondria in cultures of heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417-426.
76. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-1653.
77. Rao MS, Reddy JK. Paroxysmal-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55.
78. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25.
79. Metha K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutrition Rev 2002; 60: 289-293.
80. Albrecht H, Schook LB, Jongeneel CV. Nuclear migration of NF-KB correlates with TNF-mRNA accumulation. J Inflamm 1995; 45: 64-71.
81. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity and diet induced insulin resistance with salicylates or targeted disruption of IKK-beta. Science 2001; 293: 1673-1677.
82. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F. Gene expression of TNF-α and TNF receptors, p55 and p75. J Hepatol 2001; 34: 1158-1163.
83. Yang S, Zhu H, Li Y, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-268.
84. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.
85. Tilg H, Diehl AM. Cytokines in alcoholic and non alcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-1476.
86. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullogh AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
87. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
88. Alexander JF, Lischner MW, Galambos JT. Natural history of alcoholic hepatitis. II: the long-term prognosis. Am J Gastroenterol 1971; 56: 515-525.
89. Clark JM, Diehl AM. Non alcoholic fatty liver disease. An underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004.
90. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-155.
91. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and post-transplant non-alcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
92. Ratzui V, Bonhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-1493.
93. Hui JM, Chitturi S, Farrell GC, George J. The long-term outcome of cirrhosis related to non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2002; 17: A154.
94. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neil R, McCullogh AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850.
95. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.
96. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-723.
97. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Over-weight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
98. Soresen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Ols JH, Viltrup H. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003; 36: 356-359.
99. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36, 1349-1354.
100. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
101. Musso G, Gambino R, De Micheli F, Cassader M, Pizzetto M, Durazzo M, Fagà E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-916.
102. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.
103. Sanyal AJ. American Gastroenterological Association Medical Position Statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1725.
104. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA dietary guidelines: revision 2000. A statement for healthcare professionals from the nutrition committee of the American Heart Association. Stroke 2000; 31: 2751-2766.
105. Clark MJ, Sterrett JJ, Carson DS. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000; 22: 899-910.
106. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat treatment of NASH: a case series. Am J Gastroenterol 2003; 98: 926-930.
107. Coyle WJ, Delaney N, Yoshihashi A, Lawson P. Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology. Gastroenterology 1999; 116: A1198.
108. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
109. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
110. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-525.
111. Acosta RC, Molina EG, O'Brien CB, Cobo MC, Amaro R, Neff GW, Schiff ER. The use of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology 2001; 120: A546.
112. Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, Nishimura T. A pilot study of a thiazolidinediones, pioglitazone, in nonalcoholic steatohepatitis. Hepatology 2002; 36: 406A.
113. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oivier D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
114. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-1467.
115. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
116. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999; 353: 1802.
117. Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH. Gastroenterology 2001; 120: A544.
118. Nair S, Wiseman M. HMG-CoA reductase inhibitors in no alcoholic fatty liver disease. is their potential hepatotoxicity an issue in these patients? A case control study based on histology. Hepatology 2002; 36: 409A.
119. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
120. Angulo P, Lindor K. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-88.
121. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-752.
122. Rodriguez CMP, Fan GS, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 165-178.
123. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, Inaba K, Sakamoto Y, Okanoue T, Kashima K. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 24: 537-542.
124. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002; 64: 1661-1667.
125. Guma G, Viola L, Thomé M, Galdame O, Alverez E. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial. Hepatology 1997; 26: 387A.
126. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis. Hepatology 1998; 28: 386A.
127. Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized double-blind, placebo controlled trial. Hepatology 2002; 36: 412A.
128. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-2717.
129. Miglio F, Rovati LC, Santoro A, Semikar I. Efficacy and safety of oral beatine glucuronate in non-alcohol steatohepatitis. A double-blind, randomized parallel group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50: 722-727.
130. Levine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-738.
131. van Tits LJ, Demaker PN, de Graaf J, Hak-Lemmers HL, Stalenhoef AF. A-Tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. Am J Clin Nutr 2000; 71: 458-464.
132. Houglum K, Venkataramuni A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-1073.
133. Hasewaga T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β level and efficacy of α-tocopherol in patients with non-alcoholic hepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-1672.
134. Macdonald GA, Dixon J, Powell LW. Effect of phlebotomy on serum ALT levels in patients with non-alcoholic steatohepatitis and stainable hepatic iron. Hepatology 2001; 34: 457A.
135. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 931-939.
136. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003; 125: 1053-1059.
137. Garcia-Monzon C, Martin-Perez E, Lo Iacono O, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R. Characterization of pathogenetic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-724.
138. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
139. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
140. Willner IR, Waters B, Patil SR. Ninety patients with non-alcoholic steatohepatitis. insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961.
141. Rrozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
142. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
143. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970; 282: 829-834.
144. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating non-alcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-1022.
145. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83-88.
146. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229.
147. Luyckx FH, Lefebre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
148. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci 1987; 32: 441-445.
149. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-241.
150. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107.
151. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104: 23-31.
152. Merat S, Malekzadeh R, Sohrabi MZ, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418.
153. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996; 403: 607-613.
154. Fu CS, Esrason K, Alshak NS, Conteas CN, Simmons VJ. Dietary lecithin, anti-oxidant and vitamin B complex (LAB) decrease hepatic steatosis in patients with NASH. Gastroenterology 1998; 114: A1243.
155. Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. Gastroenterology 2000; 118: A1444.